Table 6 Subgroup analysis for female
Cardiovascular diseases | Cerebrovascular diseases | Heart dysfunction | Composite outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | |||||
HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | |||||
Age | ||||||||||||
20–30 (n = 33,415) | 1099 | 1229 | 0.904 (0.834, 0.981) | 59 | 94 | 0.639 (0.461, 0.885) | 115 | 151 | 0.774 (0.608, 0.987) | 1143 | 1301 | 0.888 (0.82, 0.962) |
30–40 (n = 10,393) | 372 | 517 | 0.764 (0.668, 0.872) | 39 | 72 | 0.579 (0.392, 0.855) | 59 | 83 | 0.771 (0.552, 1.076) | 399 | 569 | 0.743 (0.654, 0.845) |
Race | ||||||||||||
Black or African American (n = 6761) | 268 | 300 | 0.892 (0.757, 1.052) | 22 | 32 | 0.689 (0.4, 1.186) | 49 | 66 | 0.743 (0.513, 1.075) | 283 | 322 | 0.877 (0.748, 1.029) |
White (n = 23,141) | 825 | 953 | 0.893 (0.814, 0.981) | 41 | 83 | 0.511 (0.352, 0.743) | 86 | 109 | 0.819 (0.617, 1.087) | 857 | 1014 | 0.872 (0.796, 0.955) |
Asian (n = 3428) | 60 | 77 | 0.862 (0.615, 1.208) | 11 | 10* | 3.128 (0.996, 9.825) | 10* | 10* | 0.573 (0.172, 1.903) | 66 | 80 | 0.914 (0.66, 1.267) |
Other race (n = 2507) | 83 | 83 | 0.978 (0.722, 1.326) | 10* | 10* | 0.494 (0.123, 1.974) | 11 | 11 | 0.98 (0.425, 2.26) | 86 | 88 | 0.956 (0.71, 1.287) |